The Shotlee Journal
Browse Shotlee articles about Mounjaro.
Showing 9 / 801 Mounjaro articles
Eli Lilly's newly launched oral weight loss medication, Foundayo, has demonstrated significant early traction in the US market, with thousands of prescriptions issued within its first two weeks. This launch marks a pivotal moment in the evolving landscape of weight management therapies, particularly in the context of established injectables like semaglutide (Wegovy).
Hydration is no longer just for athletes. Discover why functional beverages infused with electrolytes are becoming a daily wellness essential, especially with the rise of GLP-1 medications.
Actor Jeremy Renner shares his intense recovery journey following a near-fatal accident, detailing the use of peptide therapy, hyperbaric treatments, and the importance of data tracking in modern wellness.
Discover the fascinating connection between your gut microbiome, the food you eat, and the natural hormones that regulate appetite and metabolism. Learn how these internal systems are similar to groundbreaking weight loss medications like Ozempic, Wegovy, and Mounjaro.
Social media trends and GLP-1 medications are reshaping how Utah students view health. Explore the balance between medical weight management and sustainable habits.
A recent analysis published in JAMA Ophthalmology reveals a significant increase in NAION risk associated with semaglutide compared to SGLT2 inhibitors, though absolute risk remains low.
New research suggests that GLP-1 receptor agonists, known for their roles in diabetes and weight management, may offer significant cardiovascular protection for patients undergoing complex procedures like TAVR and carotid artery stenting.
Many individuals experience remarkable initial success with Tirzepatide, only to find their progress unexpectedly stalling. This phenomenon, known as 'Plateau Panic,' is a growing concern. This article delves into why these plateaus occur, what they signify, and the advanced strategies available to help you regain momentum.
Eli Lilly Australia has announced that Mounjaro (tirzepatide) will not be listed on the Pharmaceutical Benefits Scheme (PBS) for Type 2 Diabetes, citing unsustainable funding conditions. This decision highlights ongoing challenges in accessing modern GLP-1 and GIP therapies.
